Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?
Narrative review published in European heart journal (2013)
Abstract
Decision making with regard to thromboprophylaxis should be based upon the absolute risks of stroke/thromboembolism and bleeding and the net clinical benefit for a given patient. As a consequence, a crucial part of atrial fibrillation (AF) management requires the appropriate use of thromboprophylaxis, and the assessment of stroke as well as bleeding risk can help inform management decisions by clinicians. The objective of this review article is to provide an overview of stroke and bleeding risk assessment in AF. There would be particular emphasis on when, how, and why to use these risk stratification schemes, with a specific focus on the CHADS2 [congestive heart failure, hypertension, age, diabetes, stroke (doubled)], CHA2DS2-VASc [congestive heart failure or left ventricular dysfunction, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65-74 and sex category (female)], and HAS-BLED [hypertension (i.e. uncontrolled blood pressure), abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR (if on warfarin), elderly (e.g. age >65, frail condition), drugs (e.g. aspirin, NSAIDs)/alcohol concomitantly] risk scores.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
This review explains when, how, and why to assess stroke and bleeding risk in atrial fibrillation, focusing on the CHADS2, CHA2DS2-VASc, and HAS-BLED scores to guide thromboprophylaxis decisions based on absolute risks and net clinical benefit.
Context
This review article provides an overview of stroke and bleeding risk assessment in atrial fibrillation, focusing on the CHADS2, CHA2DS2-VASc, and HAS-BLED risk stratification schemes to guide thromboprophylaxis decisions. The content is entirely within the domain of oral anticoagulant risk stratification for cardiac patients. The abstract addresses anticoagulant decision-making frameworks but makes no reference to leeches, hirudotherapy, hirudin, or any leech-derived substance.
Citation
Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026